• The top 100 most-cited articles on medication-related osteonecrosis of the jaw (MRONJ) from 2004-2024 accumulated 12,337 citations, with the US, University of London, and Salvatore L. Ruggiero leading in country, institution, and author productivity.
• Hot keywords include risk factors, bisphosphonates, cancer, and osteoclasts, with 'Denosumab' as a burst keyword, indicating a shift toward understanding the role of RANKL inhibitors in MRONJ.
• High-level evidence (cohort studies, RCTs, systematic reviews, and clinical guidelines) has driven standardization of diagnosis and management, moving from case reports to evidence-based practice.
• Future directions emphasize tissue engineering and regenerative medicine, including 3D-printed scaffolds, stem cell therapy, and novel biomaterials, to enhance bone repair and regeneration in MRONJ.